Esperion Therapeutics
ESPR
ESPR
132 hedge funds and large institutions have $241M invested in Esperion Therapeutics in 2022 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 43 increasing their positions, 30 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
10% less capital invested
Capital invested by funds: $268M → $241M (-$26.8M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
101.72% less ownership
Funds ownership: 184.38% → 82.66% (-102%)
Holders
132
Holding in Top 10
2
Calls
$7.04M
Puts
$1.17M
Top Buyers
| 1 | +$8.17M | |
| 2 | +$7.06M | |
| 3 | +$4.24M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.39M |
| 5 |
JPMorgan Chase & Co
New York
|
+$2.95M |
Top Sellers
| 1 | -$25M | |
| 2 | -$7.3M | |
| 3 | -$4.7M | |
| 4 |
HF
HRT Financial
New York
|
-$1.18M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.15M |